Ergoteles’s Acorda Therapeutics ACOR Stock Holding History

Ergoteles’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-665	Closed	-$6K	–	2159
2022 Q2	$6K	Buy	+665	New	+$11.8K	﹤0.01%	1594

Other funds holding ACOR

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

CCA

Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Saltoro Capital Dallas, Texas $30K AUM 24.79% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ergoteles's ACOR Position: Q3 2022 in Review

Ergoteles sold out of Acorda Therapeutics (ACOR) in Q3 2022, closing a stake of 665 shares — an estimated $6K sold.

Ergoteles first reported a position in ACOR in Q2 2022 and held it in 1 quarter. The position peaked at $6K in Q2 2022. 33 funds tracked by Wall St. Rank hold ACOR as of Q3 2022.

Ergoteles reported no remaining Acorda Therapeutics position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 665 Acorda Therapeutics shares in Q3 2022, an estimated $6K.
Ergoteles first reported a position in Acorda Therapeutics in Q2 2022 and held it in 1 quarter.
Ergoteles's Acorda Therapeutics position peaked at $6K in Q2 2022.
33 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.